Targeting Cathepsin E in Pancreatic Cancer by a Small Molecule Allows In Vivo Detection
When resectable, invasive pancreatic ductal adenocarcinoma (PDAC) is most commonly treated with surgery and radiochemotherapy. Given the intricate local anatomy and locoregional mode of dissemination, achieving clean surgical margins can be a significant challenge. On the basis of observations that...
Main Authors: | Edmund J. Keliher, Thomas Reiner, Sarah Earley, Jenna Klubnick, Carlos Tassa, Andrew J. Lee, Sridhar Ramaswamy, Nabeel Bardeesy, Douglas Hanahan, Ronald A. DePinho, Cesar M. Castro, Ralph Weissleder |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2013-07-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558613800632 |
Similar Items
-
Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma.
by: Kimberly A Kelly, et al.
Published: (2008-04-01) -
Bioorthogonal small molecule imaging agents allow single-cell imaging of MET.
by: Eunha Kim, et al.
Published: (2013-01-01) -
Deficiency for the cysteine protease cathepsin L impairs Myc-induced tumorigenesis in a mouse model of pancreatic neuroendocrine cancer.
by: Nicola R Brindle, et al.
Published: (2015-01-01) -
Imaging Therapeutic PARP Inhibition In Vivo through Bioorthogonally Developed Companion Imaging Agents
by: Thomas Reiner, et al.
Published: (2012-03-01) -
Study of the expression of cathepsins in histological material from pancreatic lesions
by: Juan Martínez, et al.